Sertraline hepatotoxicity: A case report and review of the literature on selective serotonin reuptake inhibitor hepatotoxicity

Digestive Diseases and Sciences

Volumn 48, Issue 5, 2003, Pages 939-944

  Persky, Seth ^a   Reinus, John F ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Hepatitis; Hepatotoxicity; Sertraline; SSRI; Zoloft

Indexed keywords

AMINOTRANSFERASE; AMITRIPTYLINE; PARACETAMOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ABDOMINAL PAIN; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; AUTOIMMUNE HEPATITIS; CASE REPORT; CHILL; CLINICAL FEATURE; DEPRESSION; FEMALE; HEADACHE; HUMAN; LIVER FAILURE; LIVER TOXICITY; NAUSEA; PRIORITY JOURNAL; TOXIC HEPATITIS; VOMITING;

ADULT; BIOPSY, NEEDLE; DEPRESSIVE DISORDER; FEMALE; FOLLOW-UP STUDIES; HEPATITIS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER FUNCTION TESTS; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SEVERITY OF ILLNESS INDEX;

EID: 0037404964     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023007831047     Document Type: Article

References (29)

1. Product Information: Zoloft (Sertraline) tablets. 1992. Pfizer Pharmaceuticals. Rev G 6/99.
2. Cohn CK, Shrivastava R, Mendels J, Cohn JB, Fabre LF, Claghorn JL, Dessain EC, Itil TM, Lautin A: Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 51 (12, suppl B):28-33, 1990
3. Aguglia E, Casacchia M, Cassano GB, Faravelli C, Ferrari G, Giordano P, Pancheri P, Ravizza L, Trabucchi M, Bolino F, et al: Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 8:197-202, 1993
4. Baumel B: Double blind comparison of sertraline and placebo in patients with panic disorder (poster). Presented at the 20th Collegium International Neuro-Psychopharmacologicum (CINP), June 23-27, 1996, Melbourne, Australia.
5. Gorman J, Wolkow R: Sertraline as a treatment for panic disorder. Neuropsychopharmacology 10 (35 pt 2):1975, 1994
6. Pollack M: Double blind, flexible dose comparison of sertraline and placebo in outpatients with panic disorder (poster). Presented at the 35th annual meeting of the American College of Neuropsychopharmacology, December 9-13, 1996, San Juan, Puerto Rico
7. Kronig MH, Apter J, Asnis G, Bystritsky A, Curtis G, Ferguson J, Landbloom R, Munjack D, Riesenberg R, Robinson D, Roy-Byrne P, Phillips K, Du Pont IJ: Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J Clin Psychopharmacol. 19 (2):172-176, 1999
8. March JS, Biederman J, Wolkow R: Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 280 (20):1752-1756, 1998
9. Chouinard G, Goodman W, Greist J, Jenike M, Rasmussen S, White K, Hackett E, Gaffney M, Bick PA: Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull 26(3):279-284, 1990
10. Farrell GC: Liver disease caused by drugs, anesthetics, and toxins. In: Gastrointestinal Disease. M Feldman, BF Scharschmidt, MH Sleisenger (eds). Philadelphia, WB Saunders, 1998, pp 1221-1252
11. Hautekeete ML, Colle I, van Vlierberghe H, Elewaut A: Symptomatic liver injury probably related to sertraline. Gastroenterol Clin Biol 22:364-365, 1998
12. Kim KY, Hwang W: Acute liver damage possibly related to sertraline and venlafaxine ingestion. Ann Pharmacother 33:381-382, 1999
13. Menon RR, Howard R: Sertraline and liver toxicity in the elderly. Int J Geriatr Psychiatr 9:332-334, 1994
14. Barbey JT, Roose SP: SSR1 Safety in overdose. J Clin Psychiatry 59(suppl 15):42-48, 1998
15. Castiella A, Arenas JI: Fluoxetine Hepatotoxicity. Am J Gastroenterol 89(3):458-459, 1994
16. Friedenberg FK, Rothstein KD: Hepatitis secondary to Fluoxetine treatment. Am J Psychiatry 153(4):580, 1996
17. Bobichon R, Bernard G, Mion F: Atteinte hepatique aigue lors d'un traitement par la fluoxetine. Gastroenterol Clin Biol 17:406-407, 1993 (letter)
18. Mars F, Dumas de la Roque GD: Hepatite aigue lors du traitement par la fluoxetine. Gastroenterol Clin Biol 15:270-271, 1991 (letter)
19. Cai Q, Benson MA, Talbot TJ, Devadas G, Swanson HJ, Olson JL, Kirchner JP: Acute hepatitis due to fluoxetine therapy. Mayo Clin Proc 74:692-694, 1999
20. Johnston DE, Wheeler DE: Chronic hepatitis related to use of fluoxetine. Am J Gastroenterol 92:1225-1226, 1997
21. Benbow SJ, Gill G: Paroxetine and hepatotoxicity: BMJ 314:1387, 1997
22. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE: The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34:262-265, 1992
23. Czaja AJ; Diagnosis, prognosis, and treatment of classical autoimmune chronic active hepatitis. In EL Krawitt, RH Eisner (eds). Autoimmune Liver Disease. New York, Raven Press, 1991
24. Federal Trade Commission Internet Site, www.ftc.gov
25. Official Zoloft Internet Site, www.zoloft.com
26. National Library of Medicine's Pubmed Internet Site, www.ncbi.nlm.nih.gov/Pubmed
27. Verrico MM, Nace DA, Towers AL: Fulminant chemical hepatitis possibly associated with donepezil and sertraline therapy. J Am Geriatr Soc 48(12):1659-1663, 2000
28. Cadranel JF, Di Martino V, Cazier A, Pras V, Bachmeyer C, Olympio P, Gonzenbach A, Mofredj A, Coutarel P, Devergie B, Biour M: Atrium and paroxetine-related severe hepatitis. J Clin Gastroenterol 28(1):52-55, 1999
29. Helmchen C, Boerner RJ, Meyendorf R, Hegerl U: Reversible hepatotoxicity of paroxetine in a patient with major depression. Pharmacopsychiatry 29(6):223-226, 1996